SCHEMBL756185

SCHEMBL756185

NC(=NO)c1cccc(Oc2ccc3c(c2)S(=O)(=O)NCCO3)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.44
TNKS O95271 1/20 0.36
PARP15 Q460N3 1/20 0.36
PARP14 Q460N5 1/20 0.36
PARP10 Q53GL7 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
PARP2 Q9UGN5 1/20 0.36
GRIA2 P42262 7/20 0.36
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
GFER P55789 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
FAAH O00519 1/20 0.33
NPC1 O15118 2/20 0.32
MAPT P10636 2/20 0.32
PKM P14618 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CTNNB1 P35222 1/20 0.32
WNT3A P56704 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL756184 0.88 LMNA (0.35) KEAP1TNKSPARP15PARP14PARP10
SCHEMBL756187 0.88 LMNA (0.35) KEAP1TNKSPARP15PARP14PARP10
SCHEMBL760979 0.85 KEAP1 (0.48) KEAP1GRIA2FAAHNPC1RAB9A
SCHEMBL757860 0.83 KEAP1 (0.40) KEAP1GRIA2LMNANPC1MAPT
SCHEMBL757862 0.83 KEAP1 (0.40) KEAP1GRIA2LMNANPC1MAPT
SCHEMBL1973344 0.81 TNKS (0.38) TNKSPARP15PARP14PARP10TNKS2
SCHEMBL753235 0.81 KEAP1 (0.60) KEAP1GRIA2ALOX5
SCHEMBL783111 0.80 KEAP1 (0.43) KEAP1GRIA2KMT2ALMNANPC1
SCHEMBL762296 0.79 GRIA2 (0.55) KEAP1GRIA2NPC1RAB9ASMN1; SMN2
SCHEMBL760980 0.74 AKR1C3 (0.48) FAAHNPC1RAB9ACTNNB1WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569285-B2 Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-10-29 US disclosed
EP-2431360-B1 Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors SERVIER LAB (FR) 2013-04-17 EP disclosed
US-20120071462-A1 Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-22 US disclosed
EP-2431360-A1 Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors Les Laboratoires Servier (FR) 2012-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071462-A1 Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them GABRA1, GRM1, GABRA5 KEAP1 2482/4885TNKS 2901/4885PARP15 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.